- Home
- GDEV vs NGNE Comparison
GDEV vs NGNE Comparison
Compare GDEV & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEV
- NGNE
- Stock Information
- Founded
- GDEV 2009
- NGNE 2003
- Country
- GDEV Cyprus
- NGNE United States
- Employees
- GDEV N/A
- NGNE N/A
- Industry
- GDEV EDP Services
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- GDEV Technology
- NGNE Health Care
- Exchange
- GDEV Nasdaq
- NGNE Nasdaq
- Market Cap
- GDEV 520.6M
- NGNE 471.1M
- IPO Year
- GDEV N/A
- NGNE N/A
- Fundamental
- Price
- GDEV $26.00
- NGNE $34.52
- Analyst Decision
- GDEV Buy
- NGNE Strong Buy
- Analyst Count
- GDEV 2
- NGNE 6
- Target Price
- GDEV $70.00
- NGNE $63.80
- AVG Volume (30 Days)
- GDEV 6.9K
- NGNE 353.3K
- Earning Date
- GDEV 11-14-2024
- NGNE 11-15-2024
- Dividend Yield
- GDEV N/A
- NGNE N/A
- EPS Growth
- GDEV N/A
- NGNE N/A
- EPS
- GDEV 2.48
- NGNE 0.18
- Revenue
- GDEV $443,165,000.00
- NGNE $925,000.00
- Revenue This Year
- GDEV N/A
- NGNE N/A
- Revenue Next Year
- GDEV $6.12
- NGNE N/A
- P/E Ratio
- GDEV $10.50
- NGNE $189.06
- Revenue Growth
- GDEV N/A
- NGNE N/A
- 52 Week Low
- GDEV $19.00
- NGNE $12.49
- 52 Week High
- GDEV $42.76
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- GDEV 39.77
- NGNE 35.74
- Support Level
- GDEV $24.30
- NGNE $35.60
- Resistance Level
- GDEV $32.60
- NGNE $43.24
- Average True Range (ATR)
- GDEV 2.94
- NGNE 6.02
- MACD
- GDEV -1.03
- NGNE -2.86
- Stochastic Oscillator
- GDEV 9.21
- NGNE 0.00
About GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.